If You Invested in Klotho Neurosciences, Inc. (KLTO)

Klotho Neurosciences, Inc. (NASDAQ: KLTO) is a U.S.-based biogenetics and biotechnology company in the healthcare sector. According to the company’s public disclosures, Klotho focuses on the development of disease-modifying cell and gene therapies that use a protein derived from a patented form of the human “anti-aging” Klotho gene, often referred to as s-KL. Its work centers on neurodegenerative and age-related disorders, positioning the Klotho gene and related pathways at the core of its therapeutic strategy.

The company describes itself as advancing Klotho-based therapeutics for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and Parkinson’s disease, and more broadly as pursuing technologies that support healthy brain function, organ health, and longevity. Klotho’s portfolio consists of proprietary cell and gene therapy programs that use DNA and RNA as therapeutics, together with genomics-based diagnostic assays. These programs are designed around a protein derived from a patented form of the Klotho gene and novel delivery systems intended to transform and improve treatment of neurodegenerative and age-related disorders.

Focus on the Klotho “anti-aging” gene

The company highlights the human Klotho gene as strongly linked to aging and longevity. Public statements note that Klotho levels decline with age and that this decline is associated with age-related disorders such as cardiometabolic disease, neurodegeneration, cancer, sarcopenia (muscle wasting), osteoporosis, and general fatigue. Silencing of the Klotho gene has been described by the company as accelerating multi-organ deterioration. Klotho emphasizes the role of alpha-Klotho and beta-Klotho proteins, as well as related factors such as FOXO3 and anti-myostatin, in its evaluation of potential longevity indicators.

In company communications, the Klotho gene has been characterized as a “master gene” with pleiotropic actions that modulate cellular pathways including insulin resistance, insulin-like growth factor-1, FOXO3 transcription factors, and Wnt signaling. These pathways are described as contributing to the reduction of inflammatory and mitochondrial oxidative stresses and other cell-damaging mechanisms that can be influenced by alpha-Klotho protein isoforms, including soluble Klotho and secreted-Klotho.

Therapeutic programs and pipeline orientation

Klotho Neurosciences reports that its current portfolio includes proprietary cell and gene therapy programs using DNA and RNA as therapeutics, along with genomics-based diagnostic assays. Public materials reference specific product candidates identified as KLTO-101, KLTO-202, and KLTO-303, which are associated with Alzheimer’s and Parkinson’s diseases, ALS and other motor neuron diseases, and aging-related pathologies, respectively. The company has also referred to KLTO-301 in earlier descriptions of its pipeline.

The company has announced that it has begun manufacturing and development activities for KLTO-101 and KLTO-202 and has highlighted KLTO-202 in particular. Klotho reports that the U.S. Food and Drug Administration has granted Orphan Drug Designation for KLTO-202 for the treatment of ALS, which the company cites as regulatory recognition of the therapeutic potential of its Klotho-based programs for serious unmet medical needs.

Gene therapy manufacturing and partnerships

Klotho Neurosciences has disclosed a partnership with AAVnerGene Inc., a biotechnology company focused on adeno-associated virus (AAV) vector technologies. Under this collaboration, Klotho is using AAVnerGene’s AAV manufacturing and tissue-targeted delivery platforms, including the “AAVone” high-yield single-plasmid AAV production system and the “ATHENA” capsid engineering platform.

According to the company, AAVone is intended to simplify AAV production, increase yield, reduce impurities, shorten development time, and lower manufacturing costs compared to traditional “triple transfection” methods in HEK293 cell lines. The ATHENA platform is described as enabling specific tissue targeting of AAV vectors. Klotho has stated that it plans to use these technologies to manufacture gene therapy product candidates that combine tissue-specific promoters with the Klotho gene, aiming to produce elevated concentrations of Klotho protein in targeted tissues and organs affected by neurologic and neuromuscular diseases.

Expansion beyond neurology and longevity focus

While Klotho’s core programs target brain aging and neurodegenerative diseases such as ALS, Alzheimer’s disease, and Parkinson’s disease, the company has publicly announced that it is evaluating the acquisition of complementary technologies aimed at supporting healthy brain function, organ health, and longevity. It has indicated interest in technologies that could improve muscle strength, bone health, and other longevity indicators, with the stated goal of slowing biological aging and reducing the burden of age-related diseases.

Company communications describe efforts to assemble a team of scientists, clinicians, and business leaders focused on identifying key longevity indicators. These efforts include evaluating genes and proteins such as alpha-Klotho, beta-Klotho, FOXO3, anti-myostatin, and their isoforms. Klotho has also stated that it is exploring additional treatments that could support healthy aging and extend human longevity, building on its proprietary Klotho platform.

Corporate status, listing, and financing

Klotho Neurosciences, Inc. is incorporated in Delaware and identifies itself as an emerging growth company and a smaller reporting company under U.S. securities regulations. Its common stock trades on the Nasdaq Capital Market under the symbol “KLTO”, and its warrants trade under the symbol “KLTOW”, as disclosed in its current reports on Form 8-K.

The company has filed a registration statement on Form S-1 that relates to the potential resale of shares of common stock issuable upon conversion of its Series C Convertible Preferred Stock, as well as shares held by an existing stockholder. The S-1 describes a private placement of Series C Convertible Preferred Stock and indicates that Klotho will not receive proceeds from the resale of common stock by the selling stockholders. Klotho has also disclosed that it has raised financing through preferred stock and other arrangements, and that it has used capital to advance its programs, eliminate debt, and maintain compliance with Nasdaq listing requirements.

In a Form 8-K, the company reported receiving a delinquency notification letter from Nasdaq because its common stock did not maintain a minimum bid price of $1 per share for 30 consecutive business days, as required by Nasdaq Listing Rule 5550(a)(2). Nasdaq granted Klotho a period of 180 calendar days to regain compliance by achieving a closing bid price of at least $1 for a minimum of ten consecutive business days, and the company noted that failure to regain compliance could subject its common stock to delisting.

Strategic direction and partnerships

Klotho Neurosciences has communicated a strategy that includes advancing its Klotho-based therapeutics from preclinical development toward clinical evaluation, expanding its research capabilities, and pursuing complementary technologies and acquisitions in areas related to brain health, organ function, and longevity. The company has highlighted a binding agreement with AAVnerGene for manufacturing KLTO-202, the initiation of manufacturing for KLTO-202, and the launch of a research center in Okinawa, Japan, as steps that strengthen its preclinical research, biomarker development, and operational expertise.

The company has also discussed a prior collaboration with SkyBell that was mutually terminated, after which Klotho retained full global rights to its Klotho programs. It has indicated that it is evaluating complementary longevity-related assets and has referenced a Letter of Intent to acquire select assets from Turn Biotechnologies, Inc., including the ERA epigenetic reprogramming platform and the eTurna RNA delivery system, although it later announced that a separate Letter of Intent with Turn Biotechnologies was allowed to expire after evaluation by its board of directors.

Management and expertise

In its public statements, Klotho Neurosciences emphasizes that it is managed by a team of individuals and advisors who are described as highly experienced in biopharmaceutical product development and commercialization. The company also references key scientific advisors and inventors who have presented research on Klotho gene therapy in ALS, Alzheimer’s disease, and longevity at scientific meetings and conferences focused on Klotho-based therapies and diagnostics.

Frequently asked questions (FAQ)

• What does Klotho Neurosciences, Inc. do?
  

  Klotho Neurosciences, Inc. is a biogenetics and biotechnology company that focuses on developing disease-modifying cell and gene therapies based on a protein derived from a patented form of the human Klotho gene. Its programs target neurodegenerative and age-related disorders, and its portfolio includes proprietary DNA- and RNA-based therapeutics and genomics-based diagnostic assays.

• Which diseases does Klotho target with its Klotho-based therapies?
  

  According to the company’s disclosures, Klotho’s core programs target brain aging and neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and Parkinson’s disease. The company has also expressed interest in addressing broader age-related conditions that affect brain function, organ health, muscle strength, bone health, and other longevity indicators.

• What is the role of the Klotho gene in Klotho Neurosciences’ approach?
  

  The company highlights the Klotho gene as an “anti-aging” or “master” gene associated with aging and longevity. It reports that Klotho levels decline with age and that this decline is linked to age-related disorders. Klotho’s therapeutic approach uses a protein derived from a patented form of the Klotho gene (s-KL) and focuses on modulating cellular pathways related to inflammation, oxidative stress, and other mechanisms involved in neurodegeneration and aging.

• What are KLTO-101, KLTO-202, and KLTO-303?
  

  Klotho Neurosciences has identified KLTO-101, KLTO-202, and KLTO-303 as gene therapy product candidates in its pipeline. Public statements associate KLTO-101 with Alzheimer’s and Parkinson’s diseases, KLTO-202 with ALS and other motor neuron diseases, and KLTO-303 with aging-related pathologies. The company has announced that it has begun manufacturing and development activities for KLTO-101 and KLTO-202.

• Has any Klotho program received regulatory designations?
  

  The company reports that the U.S. Food and Drug Administration has granted Orphan Drug Designation for KLTO-202 for the treatment of ALS. Klotho describes this designation as reinforcing the therapeutic potential of its Klotho-based programs for serious unmet medical needs in neurodegenerative disease.

• How does Klotho manufacture its gene therapy candidates?
  

  Klotho has entered into a partnership with AAVnerGene Inc. to manufacture and develop its KLTO-202 gene therapy candidate using AAVnerGene’s platform technology. The company states that it is using AAVnerGene’s AAVone single-plasmid AAV production system and ATHENA capsid engineering platform to increase production efficiency, reduce impurities, shorten development time, and enable tissue-targeted delivery of Klotho gene therapy products.

• On which exchange is Klotho Neurosciences listed and what is its ticker symbol?
  

  Klotho Neurosciences, Inc. states that its common stock is listed on the Nasdaq Capital Market under the ticker symbol “KLTO.” Its warrants are listed on the same market under the symbol “KLTOW,” as disclosed in its current reports on Form 8-K.

• What is the purpose of Klotho’s S-1 registration statement?
  

  The Form S-1 filed by Klotho Neurosciences relates to the offering and resale from time to time by selling stockholders of shares of common stock issuable upon conversion of Series C Convertible Preferred Stock, and shares already held by a selling stockholder. The company states that it will not receive proceeds from the resale of these shares, and that the selling stockholders may sell the shares in public or private transactions at various prices.

• Has Klotho received any Nasdaq compliance notices?
  

  In a Form 8-K, Klotho reported receiving a delinquency notification letter from Nasdaq because its common stock did not maintain a minimum bid price of $1 per share for 30 consecutive business days, as required by Nasdaq Listing Rule 5550(a)(2). Nasdaq granted the company 180 calendar days to regain compliance by achieving a closing bid price of at least $1 for a minimum of ten consecutive business days, and the company noted that failure to do so could result in delisting.

• Is Klotho Neurosciences expanding beyond neurology?
  

  The company has announced that, in addition to its core programs in brain aging and neurodegenerative diseases, it is evaluating the acquisition of complementary technologies aimed at supporting healthy brain function, organ health, muscle strength, bone health, and other longevity indicators. Klotho describes this as an effort to expand its development programs beyond neurology while remaining anchored in its proprietary anti-aging Klotho platform.